Clinical Trial Update: A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial (CARDINAL) evaluating Bardoxolone methyl for Alport syndrome has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alport Syndrome

Drugs mentioned

• Bardoxolone Methyl (bardoxolone methyl)

Snippet

Sponsor: Biogen | Conditions: Alport Syndrome | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-10-11